Abstract
Melanoma is the most aggressive form of skin cancer and advantages stages are inevitably resistant to conventional therapeutic agents. In particular, the inability of undergo apoptosis in response to chemotherapy and other external stimuli poses a selective advantage for tumor progression, metastasis formation as well as resistance to therapy in melanoma. Herein, we will review the discovery of MDR transporters and the apoptotic mechanisms used by melanoma cells. Furthermore, the novel strategies to overcome tumor chemoresistance will also discuss. In particular, we will review the cancer stem cell hypothesis and how the failure of MDR reversal agents might increase the therapeutic index of substrate antineoplastic agents.
Keywords: multi-drug resistance (MDR) Transporter, dacarbazine, ATP binding cassette (ABC) transporters, apoptosis, Chemoresistance
Current Medicinal Chemistry
Title: Drug Resistance in Melanoma: New Perspectives
Volume: 14 Issue: 4
Author(s): Caterina A.M. La Porta
Affiliation:
Keywords: multi-drug resistance (MDR) Transporter, dacarbazine, ATP binding cassette (ABC) transporters, apoptosis, Chemoresistance
Abstract: Melanoma is the most aggressive form of skin cancer and advantages stages are inevitably resistant to conventional therapeutic agents. In particular, the inability of undergo apoptosis in response to chemotherapy and other external stimuli poses a selective advantage for tumor progression, metastasis formation as well as resistance to therapy in melanoma. Herein, we will review the discovery of MDR transporters and the apoptotic mechanisms used by melanoma cells. Furthermore, the novel strategies to overcome tumor chemoresistance will also discuss. In particular, we will review the cancer stem cell hypothesis and how the failure of MDR reversal agents might increase the therapeutic index of substrate antineoplastic agents.
Export Options
About this article
Cite this article as:
Caterina A.M. La Porta , Drug Resistance in Melanoma: New Perspectives, Current Medicinal Chemistry 2007; 14 (4) . https://dx.doi.org/10.2174/092986707779941078
DOI https://dx.doi.org/10.2174/092986707779941078 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dietary Antioxidants as Potential Pharmacological Agents for Ischemic Stroke
Current Medicinal Chemistry Anticancer Antioxidant Regulatory Functions of Phytochemicals
Current Medicinal Chemistry Selective Histone Deacetylase Inhibitors with Anticancer Activity
Current Topics in Medicinal Chemistry Ion Transporters in Brain Tumors
Current Medicinal Chemistry Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design YB-1 Activities in Oncogenesis: Transcription and Translation
Current Cancer Therapy Reviews CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology Relevance of Drug Metabolizing Enzyme Activity Modulation by Tea Polyphenols in the Inhibition of Esophageal Tumorigenesis
Medicinal Chemistry Hsp90 Inhibitor Geldanamycin and Its Derivatives as Novel Cancer Chemotherapeutic Agents
Current Pharmaceutical Design Development of Antibacterial Drugs by Targeting Toll-Like Receptors
Current Topics in Medicinal Chemistry Inhibition of Hyaluronan Synthase-3 Decreases Subcutaneous Colon Cancer Growth by Increasing Apoptosis
Anti-Cancer Agents in Medicinal Chemistry ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway
Current Molecular Medicine Cytoskeletal Alterations that Confer Resistance to Anti-tubulin Chemotherapeutics
Anti-Cancer Agents in Medicinal Chemistry Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization
Current Medical Imaging Pleiotropic Functions of Rho GTPase Signaling: A Trojan Horse or Achilles Heel for Breast Cancer Treatment?
Current Drug Targets Molecular Pharmacology and Pharmacogenomics of Artemisinin and its Derivatives in Cancer Cells
Current Drug Targets Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics Current Non-viral siRNA Delivery Systems as a Promising Treatment of Skin Diseases
Current Pharmaceutical Design Exploring siRNA Umpired Nanogels: A Tale of Barrier Combating Carrier
Current Pharmaceutical Design Innovative Formulations for the Controlled and Site-specific Delivery of Antiinflammatory Drugs
Current Pharmaceutical Design